Amber Mahar, APRN
Primary Care · Sallisaw, OKNPI 1982203444
Payments from drug & device makers
Across 533 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$902
- AstraZeneca$861
- Bayer$623
- Mylan Specialty L.p.$574
- GSK$550
- plus $4K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 107 | $1,318 |
| Novo Nordisk | 60 | $902 |
| AstraZeneca | 48 | $861 |
| Bayer | 46 | $623 |
| Mylan Specialty L.p. | 31 | $574 |
| GSK | 25 | $550 |
| Sanofi-aventis U.S. LLC | 27 | $411 |
| Lilly USA, LLC | 26 | $404 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $370 |
| Exact Sciences | 21 | $316 |
| Pfizer | 17 | $285 |
| Boehringer Ingelheim | 16 | $267 |
| Dexcom, Inc. | 4 | $217 |
| Merck | 15 | $214 |
| Supernus Pharmaceuticals, Inc. | 4 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $189 |
| Otsuka America Pharmaceutical, Inc. | 10 | $175 |
| Amgen | 10 | $142 |
| E.r. Squibb & Sons, L.L.C. | 6 | $120 |
| Novartis | 6 | $95 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $88 |
| Johnson & Johnson | 5 | $81 |
| Viatris Specialty LLC | 4 | $66 |
| Biohaven Pharmaceuticals, Inc. | 4 | $57 |
| Amarin Pharma, Inc. | 2 | $38 |
| Myriad Women's Health, Inc. | 1 | $37 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Medtronic | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Organon | 1 | $10 |
How this compares
$8,767 in reported general payments places this provider in the 95th percentile of 83 primary care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other primary care in Sallisaw
- Misty DeanOklahoma City$6K
- Melissa GingerichClaremore$6K
- Cristina SarrosaTulsa$6K
- Tamara ManningNorman$5K
- Jessica KearneyOklahoma City$5K
- Erin OlmstedOklahoma City$3K
- Divya JoykuttyOklahoma City$3K
- Stephanie PennieTulsa$3K
- Steven OrtmanTulsa$2K
- Anita AlanizArdmore$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.